Business Of Biotech cover image

Business Of Biotech

Latest episodes

undefined
Jun 30, 2025 • 57min

How To Be A Policy Advocate For Biotech With NewYorkBIO's Jennifer Hawks Bland

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Jennifer Hawks Bland, CEO of NewYorkBIO, shares insights on New York State's life sciences ecosystem while reflecting on her journey from Capitol Hill to biotech advocacy. Her experiences in politics, law, and biopharma government affairs uniquely positions her to navigate complex policy challenges while creating opportunities for biotech upstarts across New York and beyond. Jennifer also highlights key programs, capabilities, and funding on offer to early-stage biotech companies.  This episode of the Business of Biotech is brought to you by Ecolab Life Sciences. Learn more at https://www.ecolab.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
undefined
Jun 23, 2025 • 1h 5min

FDA Trials And Tribulations With Connect Biopharma's Barry Quart

We love to hear from our listeners. Send us a message. On this week's episode, Barry Quart, CEO of Connect Biopharma, weighs in on the current state of engagement between drug developers and the FDA, and how that key relationship continues to evolve under new leadership. Barry also discusses moving the company from China to San Diego, why a U.S. financial reporting structure helps attract investors, and how Connect is finding the white spaces in respiratory disease -- the company's lead candidate is a biologic drug targeting acute asthma and COPD exacerbations. This episode of the Business of Biotech is brought to you by Ecolab.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
undefined
13 snips
Jun 16, 2025 • 58min

Proactive Procurement Strategies For Biotech With Tom Wells

Tom Wells, Director of Life Sciences at 4C Associates, shares his expertise in procurement strategies tailored for emerging biotech firms. He discusses the transformative power of smart procurement during critical growth phases and argues that effective practices enhance investor confidence. Tom emphasizes viewing procurement as proactive demand flow rather than reactive supply management. His innovative ideas, including the 'Request for Outcome' approach, challenge traditional sourcing and aim to boost collaboration and creativity in supplier relationships.
undefined
Jun 9, 2025 • 1h 6min

The Discovery Of Microbes And Implications For Public Health Today, With Science Writer Thomas Levenson

We love to hear from our listeners. Send us a message. On this week's episode, Thomas Levenson, MIT professor and author of So Very Small: How Humans Discovered The Microcosmos, Defeated Germs — And May Still Lose The War Against Infectious Disease talks about what he learned in the writing of So Very Small, how cultural and political forces shape scientific progress, and what it means for drug developers, public health officials, and patients everywhere.   This episode of the Business of Biotech is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
undefined
Jun 2, 2025 • 56min

Psychedelics For Mental Health Disorders With atai's Srinivas Rao, M.D., Ph.D.

We love to hear from our listeners. Send us a message. On this week's episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders. Internal drug development efforts at atai are focused on short-duration psychedelics that can work within existing healthcare infrastructure, with the potential to transform the treatment of mental health disorders. Rao also talks about atai's hub and spoke model for investing in other psychedelic companies, what MAPS/Lykos Therapeutics got wrong in the run-up to FDA's review of Lykos's MDMA candidate for PTSD, and whether psychedelic therapies need the "trip" to catalyze network disruption and neuroplasticity in the brain. This episode of the Business of Biotech is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
undefined
15 snips
May 26, 2025 • 56min

Biotech Angel Investing With Yaniv Sneor

Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, dives into the world of life science angel investing. He shares how investors evaluate biotech startups and the importance of crafting a compelling pitch. Yaniv discusses red flags for investors, the role of syndicates, and why biotech remains a strong investment sector. He highlights the intricacies of funding timelines and offers valuable insights for emerging drug developers seeking capital in a competitive landscape.
undefined
9 snips
May 19, 2025 • 59min

Leading A tRNA Startup With Alltrna's Michelle Werner

Michelle Werner, CEO of Alltrna and advocate for rare disease treatments, shares her journey from big pharma to biotech, fueled by her child's diagnosis. She explains the revolutionary potential of engineered tRNA therapy, emphasizing its ability to address countless rare genetic diseases. The conversation dives into the innovative use of AI for drug optimization and the challenges of using lipid nanoparticles for effective tRNA delivery. Michelle also highlights the importance of support networks for women leaders in biotech and the significance of storytelling in patient advocacy.
undefined
May 12, 2025 • 40min

Executing A Product Pivot With Vir Bio's Mark Eisner, MD

Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology with a rich background at Genentech and UCSF, shares insights on the company's shift to focus on infectious diseases and oncology post-COVID. He discusses the strategic integration of Sanofi's T-cell engager platform and the prioritization of hepatitis programs. Eisner also reflects on his journey from academic medicine to biopharma, emphasizing the importance of leadership during organizational changes and the potential of innovative partnerships in drug development.
undefined
May 5, 2025 • 56min

Commercializing RNAi Therapies With Alnylam's Tolga Tanguler

Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, shares his insights on commercializing RNAi therapies. He discusses how these treatments navigate health insurance reimbursement systems and the innovative use of value-based contracts. Tanguler explores the complexities of expanding from rare diseases to larger patient populations, the evolution of biopharmaceutical sales strategies, and the importance of strategic partnerships in the industry. With a focus on enhancing patient adherence and accessibility, he outlines future priorities for biotech innovations.
undefined
Apr 28, 2025 • 56min

Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie

We love to hear from our listeners. Send us a message. On today's episode I'm speaking with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo Pharmaceuticals, and Onspira Therapeutics informs his leadership at Uniquity, a clinical-stage immunology startup backed by Blackstone Life Sciences. Lortie also walks through the formation and launch of Uniquity and provides detail on the company's business model and strategy.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app